Brief: Insilico Medicine And SK Biopharmaceuticals Collaborate On Drug Discovery For Neuroimmune Disorders
22/06/2026 05:41
BRIEF-Insilico Medicine And SK Biopharmaceuticals Collaborate On Drug Discovery For Neuroimmune Disorders June 22 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK:
INSILICO MEDICINE AND SK BIOPHARMACEUTICALS ACHIEVED AI-POWERED DRUG DISCOVERY COLLABORATION WORTH UP TO 2.5 BILLION FOR NEUROIMMUNE DISORDERS
INSILICO - INSILICO WILL BE ELIGIBLE TO RECEIVE UP TO $18 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS
Source text: ID:nPn3NpCPca
Further company coverage: 3696.HK
((Reuters.briefs@thomsonreuters.com;))
Recent news on Insilico Medicine Cayman TopCo
See all newsInSilico Medicine jumps on progress in testing of new weight-loss drug
Development Collaboration
InSilico jumps on collaboration to develop biological frontier foundation models
HK-listed InSilico Medicine climbs as chairman buys shares
Brief: Insilico Medicine Cayman Topco's Chair Purchases Aggregate 113,500 Shares In Sept 4-7